Navigation Links
Lilly Reports First-Quarter 2013 Results
Date:4/24/2013

rcent, compared with 24.4 percent in the first quarter of 2012, primarily driven by the reinstatement of the R&D tax credit in the U.S. for the first quarter of 2013 as well as the one-time impact of the R&D tax credit for 2012 that was recorded in the first quarter of 2013. Net income and earnings per share were $1.248 billion and $1.14, respectively, compared with $1.027 billion and $0.92 during the first quarter of 2012.  These increases were driven by a lower tax rate, higher other income and higher operating income.

Non-GAAP results in the first quarter of 2013 exclude items totaling $0.28 of income. For the first quarter of 2012, expenses totaling $0.01 per share were excluded. For further detail, see the reconciliation below as well as the footnotes to the non-GAAP income statement later in this press release.First Quarter20132012

% ChangeEarnings per share (reported)$1.42$0.9156%Asset impairment, restructuring and other special charges

 

0.01 

0.01Income from the transfer of exenatide commercial rights

(0.29)-Earnings per share (non-GAAP)  $1.14$0.9224% 

 

Revenue Highlights 

(Dollars in millions)

 

First Quarter

% Change
Over/(Under)20132012

2012Cymbalta®

$1,328.2$1,114.919%Humalog®

632.7590.37%Alimta®

616.8606.82%Cialis

515.0461.811%Humulin®

311.9307.71%Zyprexa

284.8562.7(49)%Forteo®

281.5271.34%Evista®

240.6256.2(6)%Strattera®

166.7158.95%Effient®

115.9115.80%Animal Health

499.1490.72%Total Revenue

$5,602.0$5,602.00%Cymbalta
For the first quarter of 2013, Cymbalta generated $1.328 billion in revenue, an increase of 19 percent compared with the first quarter of 2012.
'/>"/>

SOURCE Eli Lilly and Company
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. DiversityInc Names Lilly a Top Company for Diversity
2. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
3. Lilly Sets Date for Lilly Diabetes Pipeline Update to the Investment Community
4. Lilly Applauds Law Enforcement Officials for their Successful Investigation and Recovery of Pharmaceuticals Stolen from Connecticut Distribution Center
5. Lilly Oncology To Disclose New Pipeline Data At ASCO 2012
6. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
7. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
8. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
9. Lilly Expands Strategic Partnership with Chinese Manufacturer Novast to Serve Chinese Patients with High-Quality Branded Generic Medicines
10. Lilly Diabetes Launches 8th Annual Diabetes Summer Camp Tour With Olympian Kris Freeman
11. Lilly Declares Third-Quarter 2012 Dividend, Resumes Share Repurchase Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... , Dec. 17, 2014  IGI Laboratories, Inc. (NYSE ... closing of its offering of $125 million aggregate principal ... "Notes").  The Notes were offered and sold only to ... Securities Act of 1933, as amended (the "Securities Act"). ... rate of 3.75% per year, payable semiannually in arrears ...
(Date:12/17/2014)... RALEIGH, N.C. , Dec. 17, 2014 ... and Integrated Clinical Trial Services, LLC (ICTS), two ... clinical trials announce that they have formed a ... (i-CTMS). i-CTMS will provide a broad range of ... and medical device companies. i-CTMS will ...
(Date:12/15/2014)... 15, 2014 Registreer nu via  ... und 20. Februar sind alle akkreditierten pharmazeutischen ... ECOSYSTEM PARTNER PROGRAMM ™ 2015 in ... Diese Tagung soll dazu beitragen, der ... die neue profitablen Unternehmensdienstleistungen, die für Apotheken ...
Breaking Medicine Technology:IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 2IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 3IGI Laboratories Announces Closing of $125 Million of 3.75% Convertible Senior Notes Due 2019 4Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 2Integrated Clinical Trial Services and Clinical Trial Marketing Communications Form Joint Venture 3Symposium über Aegates Ecosystem-Partner-Programm für sichere Medikamente vom 19. - 20. Februar 2015 in Amsterdam 2
... STXS ) today announced that executive management will ... The Deutsche Bank Annual Health Care Conference in ... Stereotaxis, is scheduled to present an overview of the Company ... The JMP Securities Annual Research Conference in San Francisco.  Daniel ...
... StreamVenue Healthcare has partnered its "plug ... for Surgery At Presbyterian Hospital Dallas to foster ... StreamVenue Healthcare rolled out this year its Solution ... technology. The package includes EndoCom hardware; StreamingOR, live ...
Cached Medicine Technology:Stereotaxis to Present at Upcoming Investor Conferences 2Stereotaxis to Present at Upcoming Investor Conferences 3StreamVenue Healthcare Pacing Future of Endoscopy Technology 2
(Date:12/15/2014)... Reinberg HealthDay Reporter FRIDAY, ... should reassure the millions of American women who have migraine: ... "There is no association between migraine and breast cancer ... medicine at Harvard Medical School. "There is no positive association, ... no protective effect either." About 18 percent of American ...
(Date:12/15/2014)... December 15, 2014 The increase in prevalence ... of the main factors which is contributing to the growth ... the diagnosis and treatment of hearing loss and balance disorders ... three parts - microphone, speaker and amplifier. The global market ... of 6.01% during the period from 2014 to 2019. Some ...
(Date:12/15/2014)... 15, 2014 Emergo Group, Inc., a ... countries in North and South America, Europe, the Middle ... industry participants for its 2015 Medical Device Industry Survey. ... identify upcoming business and market trends as well as ... survey targets areas including:, , Overall ...
(Date:12/15/2014)... (PRWEB) December 15, 2014 At the ... organizations AutismOne and Focus Autism ... attendees with research on the effects of toxins to ... and intervention information. , Luminaries such as Dr. ... from abroad with esteemed, credentialed colleagues of the United ...
(Date:12/15/2014)... Kenmode Precision Metal Stamping has announced that Abid ... Assurance. He brings more than 15 years of ... manufacturers in the U.S. and abroad. , He ... Sonoco Products Company in the Protective Solutions Division, Vice ... Manager for Prince Industries, all in the Chicago area. ...
Breaking Medicine News(10 mins):Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 2Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 3Health News:Audiological Devices Market 2019 Demand for Esthetic Hearing Aids Drives the Growth, Says a Report at ReportsnReports.com 4Health News:Emergo’s Annual Survey Assessing the State of the Medical Device Industry Now Open 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 2Health News:AutismOne and Focus Autism Collaborate on Scientific Conference; International Group of Researchers to Present in Chicago, May 2015 3Health News:Kenmode Precision Metal Stamping Appoints Abid Rashid as Director of Quality Assurance 2
... CVS Caremark (NYSE: CVS ) announced ... again been recognized for customer satisfaction excellence by ... This is the third time that the Company ... center operations as providing "An Outstanding Customer Service ...
... CYBX ) today announced that the company will ... 2009 of its fiscal year ending April 24, 2009 on ... company will conduct a conference call to discuss those results ... Fiscal Year 2009 Third Quarter Results Conference Call Instructions ...
... Workouts counter functional decline, could ward off osteoarthritis, ... News) -- Exercise may play a key role ... and knee osteoarthritis (OA), two new studies show. ... following a six-week progressive strengthening program showed much ...
... cause of death with over 6 million new cases worldwide ... of cancer are diagnosed annually, and half a million Americans ... years of research, GlycoMeds ( http://www.cancer-test-kits.com ) has released the ... a way to detect it in the early stages when ...
... investigation into the shooting death of American video-journalist Brad Will has ... the discovery that one of the bullets was a ricochet. ... ... Physicians for Human Rights (PHR) charges that Mexico,s investigation into ...
... Through 2017 for Relapsing-Remitting Multiple Sclerosis, According to ... 4 Decision Resources, one of the world,s ... healthcare issues, finds that an oral disease-modifying therapy ... percent patient share in Europe and a 40 ...
Cached Medicine News:Health News:Caremark Customer Care Centers Recognized for Customer Satisfaction Excellence by J.D. Power and Associates Certified Call Center Program(SM) 2Health News:Cyberonics Announces Conference Call to Discuss Fiscal Year 2009 Third Quarter Financial Results 2Health News:Exercise Key Player in Knee Replacement Recovery 2Health News:GlycoMeds Discovery Yields Early Warning Test for Cancer 2Health News:Mexico Presents Flawed Theory in Shooting Death of American Journalist 2Health News:Mexico Presents Flawed Theory in Shooting Death of American Journalist 3Health News:Mexico Presents Flawed Theory in Shooting Death of American Journalist 4Health News:An Oral Disease-Modifying Drug for Relapsing-Remitting Multiple Sclerosis Would Earn High Patient Shares in Both Europe and the United States 2Health News:An Oral Disease-Modifying Drug for Relapsing-Remitting Multiple Sclerosis Would Earn High Patient Shares in Both Europe and the United States 3
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: